HIV-2 infection is rare in the U.S., but it is likely underreported.
HIV-2 infection differs from HIV-1 infection in clinically important ways: Viral loads tend to be lower, progression to AIDS is less likely, and the virus is intrinsically resistant to first-generation nonnucleoside reverse transcriptase inhibitors and to enfuvirtide. In some parts of the U.S. (most notably, New York City; see JW AIDS Clin Care Nov 22 2010), health officials have begun to change their HIV surveillance efforts to better differentiate between HIV-1 and HIV-2 infection. Now, CDC investigators have reevaluated all HIV-2 diagnoses reported between 1988 and mid-2010, to determine which were truly HIV-2.
The investigators classified cases as HIV-2 infection if they met any of the following criteria:
Reviewing Authors
Sophia A. Hussen, MD, MPH
Sophia A. Hussen, MD, MPH
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)